Immunologi:
Våre andre terapiområder

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}
      • div
      div

      The study evaluated 2 doses of upadacitinib, 15 mg and 30 mg QD. The results presented here are for RINVOQ (upadacitinib) 15 mg once daily, which is the approved dose for Rheumatoid Arthritis.

      SELECT-BEYOND: Study design

      A Phase 3 study investigating the efficacy and safety of RINVOQ + csDMARDs compared to placebo + csDMARDs in patients with moderate to severe RA and an inadequate response to bDMARDs1

      Primary
      RINVOQ 15 mg + csDMARD(s) vs placebo + csDMARD(s) at Week 12 for DAS28 (CRP) <3.2 or ACR20

      Safety
      Adverse events, serious adverse events, adverse events of special interest (e.g., serious infections, opportunistic infections, MACEs, VTEs, malignancies)

      ACR: American College of Rheumatology; ACR20: improvement of at least 20% in the American College of Rheumatology core criteria; bDMARD: biological disease-modifying antirheumatic drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28 (CRP): disease activity score with 28 joint count (C-reactive protein); MACE: major adverse cardiovascular event; MTX: methotrexate; QD: once daily; VTE: venous thromboembolic event.

       

      SELECT-BEYOND: Previous bDMARD received1

      Adapted from Tabel 1, Genovese MC et al. Lancet 2018;391(10139):2513-2524

      RINVOQ 15 mg: Efficacy across endpoints

      SELECT-BEYOND: Low disease activity and remission at Week 12 in patients with an inadequate response to bDMARDs (NRI)1,2

      *P≤0.001 vs placebo + csDMARD(s) 

      bDMARD: biological disease-modifying antirheumatic drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28 (CRP): disease activity score with 28-joint count (C-reactive protein); NRI: nonresponder imputation.

      div

      SELECT-BEYOND: Adverse events through 12 weeks of treatment1,2

      No patients reported tuberculosis, nonmelanoma skin cancer, or lymphoma.

      *These were oral candidiasis.
      †Most cases were mild and all but 1 was a single dermatome; 2 cases were serious.
      ‡One malignant melanoma in RINVOQ 15-mg group, Weeks 0–12.
      §One ischemic stroke in Weeks 0–12 in RINVOQ 15-mg group.

      div

      Jeg vil gjerne ha mer informasjon fra en produktspesialist.

      Mer info

      Jeg har spørsmål til medisinsk avdeling.

      Mer info

      Felleskatalogteksten finner du her

      Felleskatalogtekst

      Referanser

      1. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease- modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513‍-‍2524. doi:10.1016/S0140- 6736(18)31116-4
      2. RINVOQ SPC avsnitt 5.1, sist oppdatert 21.05.2022.

       

      NO-RNQ-200017v2.0juni/2021